Transcatheter mitral valve interventions.

Autor: Resor CD; The CardioVascular Center, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, United States of America. Electronic address: cresor@tuftsmedicalcenter.org.
Jazyk: angličtina
Zdroj: Progress in cardiovascular diseases [Prog Cardiovasc Dis] 2021 Nov-Dec; Vol. 69, pp. 84-88. Date of Electronic Publication: 2021 Nov 22.
DOI: 10.1016/j.pcad.2021.11.005
Abstrakt: While there are dozens of novel transcatheter mitral devices in various stages of development, they remain years away from FDA approval. The existing approved transcatheter mitral interventions-transcatheter edge to edge repair for primary and secondary mitral regurgitations and transcatheter mitral valve-in-valve and valve-in-ring procedures for failing surgical prostheses-have seen a marked increase in both use and published data over the past several years. Transcatheter edge to edge repair with MitraClip has revolutionized the management of functional mitral regurgitation in heart failure with demonstrated reductions in mortality and heart failure hospitalization and is an appropriate option for patients with primary mitral regurgitation at high or prohibitive surgical risk. In patients with failing surgical mitral prostheses transcatheter mitral valve-in-valve and valve-in-ring procedures are an appealing alternative to repeat mitral valve surgery. Existing data and relevant concerns for these procedures are discussed herein.
Competing Interests: Declaration of Competing Interest None.
(Copyright © 2021. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: